PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Cost reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine competitive advantage.
4.31%
Growth of 4.31% while CRVO shows flat gross profit. Bruce Berkowitz would examine quality advantage.
No Data
No Data available this quarter, please select a different quarter.
4.88%
R&D growth less than half of CRVO's 2381.80%. David Dodd would verify if efficiency advantage is sustainable.
-40.17%
G&A reduction while CRVO shows 8.55% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Operating expenses reduction while CRVO shows 83.27% growth. Joel Greenblatt would examine advantage.
-8.25%
Total costs reduction while CRVO shows 83.27% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
D&A reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine efficiency.
8.31%
EBITDA growth below 50% of CRVO's 100.00%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
8.25%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
133.19%
Other expenses growth less than half of CRVO's 2580.92%. David Dodd would verify if advantage is sustainable.
12.55%
Pre-tax income growth below 50% of CRVO's 201.76%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
175.66%
Tax expense change of 175.66% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
12.55%
Net income growth below 50% of CRVO's 201.76%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
15.52%
EPS growth below 50% of CRVO's 141.94%. Michael Burry would check for structural issues.
15.52%
Diluted EPS growth below 50% of CRVO's 54.84%. Michael Burry would check for structural issues.
3.21%
Share count reduction exceeding 1.5x CRVO's 143.25%. David Dodd would verify capital allocation.
3.21%
Diluted share reduction exceeding 1.5x CRVO's 176.95%. David Dodd would verify capital allocation.